AR122779A1 - Derivados de tetrazol como inhibidores de trpa1 - Google Patents
Derivados de tetrazol como inhibidores de trpa1Info
- Publication number
- AR122779A1 AR122779A1 ARP210101795A ARP210101795A AR122779A1 AR 122779 A1 AR122779 A1 AR 122779A1 AR P210101795 A ARP210101795 A AR P210101795A AR P210101795 A ARP210101795 A AR P210101795A AR 122779 A1 AR122779 A1 AR 122779A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- fluoroalkyl
- cycloalkyl
- morpholinyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- -1 C1−4-fluoroalkyl Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de tetrazol que son inhibidores de potencial de receptor transitorio anquirina 1 (TRPA1) y que son útiles para el tratamiento de las enfermedades que se pueden tratar mediante inhibición de TRPA1. Asimismo, composiciones farmacéuticas que lo contienen, y procesos para la preparación de dichos compuestos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde A se selecciona del grupo que consiste en fenilo, tiofenilo, benzotiofenilo o benzofuranilo, sustituidos o no sustituidos con uno, dos o tres miembros del grupo R³ que consiste en halógeno, C₁₋₄-alquilo, C₁₋₄-fluoroalquilo, C₃₋₄-cicloalquilo, C₃₋₄-ciclofluoroalquilo, O-C₁₋₄-alquilo, O-ciclopropilo y NC-; o A se selecciona del grupo que consiste en los compuestos del grupo de fórmula (2); R¹ se selecciona del grupo que consiste en C₁₋₄-alquilo, C₁₋₄-fluoroalquilo, C₃₋₆-cicloalquilo, R⁴-(H₂C)ₘ- y R⁵-(H₂C)ₙ-; en donde m es 1 ó 2; n es 2; R⁴ es C₃₋₆-cicloalquilo; R⁵ es -O-C₁₋₄-alquilo o -O-C₁₋₄-fluoroalquilo; R² se selecciona del grupo que consiste en H, C₁₋₄-alquilo, C₃₋₆-cicloalquilo, C₃₋₆-ciclofluoroalquilo, HO-C₁₋₄-alquilo-, C₁₋₄-fluoroalquilo, R⁶-(H₂C)ₚ-, R⁷-(H₂C)q-, R⁶-(H(R⁸)C)ₚ- y R⁷-(H(R⁹)C)q-; en donde p es 1 ó 2; q es 2; R⁶ se selecciona del grupo que consiste en HO-C₁₋₂-alquilo-, C₃₋₆-cicloalquilo, C-morfolinilo, C-imidazolilo y C-pirazolilo; en donde dichos C-pirazolilo, C-imidazolilo y C-morfolinilo no se sustituyen o se sustituyen con C₁₋₄-alquilo o C₁₋₄-fluoroalquilo; R⁷ se selecciona del grupo que consiste en C₁₋₄-alquil-O-, C₁₋₄-fluoroalquil-O-, C₁₋₄-alquil-S(O)₂-, N-morfolinilo, N-imidazolilo y N-pirazolilo; en donde dichos N-pirazolilo, N-imidazolilo, N-morfolinilo no se sustituyen o se sustituyen con C₁₋₄-alquilo o C₁₋₄-fluoroalquilo; R⁸ y R⁹ se seleccionan independientemente de H o C₁₋₄-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182988 | 2020-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122779A1 true AR122779A1 (es) | 2022-10-05 |
Family
ID=71401656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101795A AR122779A1 (es) | 2020-06-29 | 2021-06-28 | Derivados de tetrazol como inhibidores de trpa1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11884652B2 (es) |
| EP (1) | EP4171563A1 (es) |
| JP (1) | JP7539501B2 (es) |
| KR (1) | KR20230028547A (es) |
| CN (1) | CN115803029A (es) |
| AR (1) | AR122779A1 (es) |
| AU (1) | AU2021298800A1 (es) |
| BR (1) | BR112022021865A2 (es) |
| CA (1) | CA3181350A1 (es) |
| CL (1) | CL2022003329A1 (es) |
| CO (1) | CO2022016755A2 (es) |
| CR (1) | CR20220667A (es) |
| DO (1) | DOP2022000262A (es) |
| EC (1) | ECSP22088664A (es) |
| IL (1) | IL299175A (es) |
| MX (1) | MX2022016357A (es) |
| SA (1) | SA522441965B1 (es) |
| TW (1) | TW202216688A (es) |
| WO (1) | WO2022002782A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023015425A2 (pt) | 2021-04-14 | 2023-11-07 | Boehringer Ingelheim Int | Derivados de uracila como inibidores de trpa1 |
| IL314297A (en) * | 2022-02-03 | 2024-09-01 | De Shaw Res Llc | N3-substituted URACIL compounds as TRPA1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| JP7171567B2 (ja) * | 2016-11-28 | 2022-11-15 | エフ．ホフマン－ラ ロシュ アーゲー | 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類 |
| BR112023015425A2 (pt) | 2021-04-14 | 2023-11-07 | Boehringer Ingelheim Int | Derivados de uracila como inibidores de trpa1 |
-
2021
- 2021-06-24 US US17/356,748 patent/US11884652B2/en active Active
- 2021-06-25 WO PCT/EP2021/067470 patent/WO2022002782A1/en active Application Filing
- 2021-06-25 CN CN202180045969.9A patent/CN115803029A/zh active Pending
- 2021-06-25 CR CR20220667A patent/CR20220667A/es unknown
- 2021-06-25 JP JP2022578729A patent/JP7539501B2/ja active Active
- 2021-06-25 AU AU2021298800A patent/AU2021298800A1/en active Pending
- 2021-06-25 CA CA3181350A patent/CA3181350A1/en active Pending
- 2021-06-25 IL IL299175A patent/IL299175A/en unknown
- 2021-06-25 EP EP21735303.6A patent/EP4171563A1/en active Pending
- 2021-06-25 MX MX2022016357A patent/MX2022016357A/es unknown
- 2021-06-25 BR BR112022021865A patent/BR112022021865A2/pt unknown
- 2021-06-25 KR KR1020237003324A patent/KR20230028547A/ko unknown
- 2021-06-28 AR ARP210101795A patent/AR122779A1/es unknown
- 2021-06-28 TW TW110123608A patent/TW202216688A/zh unknown
-
2022
- 2022-11-21 EC ECSENADI202288664A patent/ECSP22088664A/es unknown
- 2022-11-22 CO CONC2022/0016755A patent/CO2022016755A2/es unknown
- 2022-11-22 DO DO2022000262A patent/DOP2022000262A/es unknown
- 2022-11-25 CL CL2022003329A patent/CL2022003329A1/es unknown
- 2022-12-29 SA SA522441965A patent/SA522441965B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230028547A (ko) | 2023-02-28 |
| ECSP22088664A (es) | 2022-12-30 |
| EP4171563A1 (en) | 2023-05-03 |
| DOP2022000262A (es) | 2023-01-31 |
| SA522441965B1 (ar) | 2024-07-21 |
| TW202216688A (zh) | 2022-05-01 |
| WO2022002782A1 (en) | 2022-01-06 |
| AU2021298800A1 (en) | 2022-11-24 |
| BR112022021865A2 (pt) | 2023-01-24 |
| US11884652B2 (en) | 2024-01-30 |
| US20220002270A1 (en) | 2022-01-06 |
| CN115803029A (zh) | 2023-03-14 |
| IL299175A (en) | 2023-02-01 |
| CA3181350A1 (en) | 2022-01-06 |
| MX2022016357A (es) | 2023-01-24 |
| CO2022016755A2 (es) | 2022-11-29 |
| JP7539501B2 (ja) | 2024-08-23 |
| CR20220667A (es) | 2023-02-03 |
| JP2023531924A (ja) | 2023-07-26 |
| CL2022003329A1 (es) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| PH12021550604A1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| EA202091267A1 (ru) | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 | |
| AR122779A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| BR112021020637A2 (pt) | Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia | |
| AR063878A1 (es) | Compuestos de pirrol-piridina y composicion farmaceutica | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR121676A1 (es) | DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1 | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides | |
| CL2023000670A1 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR116877A1 (es) | 3-amino-piridazinas como inhibidores de atx | |
| EA202092819A1 (ru) | Соединения | |
| AR122778A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR123784A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR110252A1 (es) | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam | |
| CL2023000837A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR116303A1 (es) | Compuesto de heteroarilpirimidina y formulación para el control de organismos nocivos | |
| AR098583A1 (es) | Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición | |
| AR127836A1 (es) | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer |